Can Replacing CA125 with HE4 in Risk of Malignancy Indices 1–4 Improve Diagnostic Performance in the Presurgical Assessment of Adnexal Tumors?

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">FIGO stage</td><td class="align_center">Number of patients (%)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">IA</td><td class="align_center">9 (17.30%)</td></tr><tr><td class="align_left">IC</td><td class="align_center">7 (13.46%)</td></tr><tr><td class="align_left">IIA</td><td class="align_center">4 (7.69%)</td></tr><tr><td class="align_left">IIC</td><td class="align_center">1 (1.92%)</td></tr><tr><td class="align_left">IIIA</td><td class="align_center">2 (3.85%)</td></tr><tr><td class="align_left">IIIB</td><td class="align_center">2 (3.85%)</td></tr><tr><td class="align_left">IIIC</td><td class="align_center">25 (48.08%)</td></tr><tr><td class="align_left">IVB</td><td class="align_center">2 (3.85%)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>FIGO: Fédération Internationale de Gynécologie et d’Obstétrique.<br/></td></tr></table>

Distribution of FIGO stages of malignant adnexal pathologies.

BioMed Research International

tab3

Table 3

Table 3: Can Replacing CA125 with HE4 in Risk of Malignancy Indices 1–4 Improve Diagnostic Performance in the Presurgical Assessment of Adnexal Tumors? 

Table 3 | Can Replacing CA125 with HE4 in Risk of Malignancy Indices 1–4 Improve Diagnostic Performance in the Presurgical Assessment of Adnexal Tumors? 